Filed in archive
Corporate and Industrial News
by ruth on April 13, 2007

VaxImmune is a proprietary Toll-like receptor 9 (TLR9) agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
VaxImmune is currently under clinical trials for various cancer, infectious disease and biowarfare applications.
Source: Coley Pharmaceutical
Photo: TLR Therapeutics, Coley Pharmaceuticals
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/63383
Mr Wong
Vote for Merck Licenses Coley Pharma's VaxImmune for $4 Million:
|
Rating: 9.67 out of 3 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







